北京大学学报(医学版) ›› 2021, Vol. 53 ›› Issue (4): 814-817. doi: 10.19723/j.issn.1671-167X.2021.04.034

• 病例报告 • 上一篇    

TAFRO综合征1例

周广平1,周倩云2,Δ(),朱继红1   

  1. 1.北京大学人民医院急诊科,北京 100044
    2.北京大学首钢医院重症医学科,北京 100144
  • 收稿日期:2021-06-16 出版日期:2021-08-18 发布日期:2021-08-25
  • 通讯作者: 周倩云 E-mail:13521349450@163.com

A case report of TAFRO syndrome

ZHOU Guang-ping1,ZHOU Qian-yun2,Δ(),ZHU Ji-hong1   

  1. 1. Department of Emergency, Peking University People’s Hospital, Beijing 100044, China
    2. Intensive Care Unit, Peking University Shougang Hospital, Beijing 100144, China
  • Received:2021-06-16 Online:2021-08-18 Published:2021-08-25
  • Contact: Qian-yun ZHOU E-mail:13521349450@163.com

RICH HTML

  

关键词: TAFRO综合征, Castleman病, 肾功能不全, 淋巴结活检, 肾活检

Abstract:

The study is to improve clinicians’ understanding of TAFRO syndrome, to explore the diagnosis and treatment of TAFRO syndrome and to identify TAFRO syndrome in the early stage. The clinical manifestations, laboratory examination results, imaging manifestations, diagnosis and treatment of TAFRO syndrome were reported, and the literature of TAFRO syndrome was reviewed. The main clinical manifestations of the female were intermittent vaginal bleeding, fever, depressive edema of both legs, red blood cell and thrombocytopenia, and renal function deterioration. The results showed that leukocytes increased, anemia, thrombocytopenia and severe renal dysfunction were found; With fever, C-reactive protein and procalcitonin increased significantly, bone penetration suggested that granulocyte proliferation was active, and megakaryocytes were seen. But anti-infection treatment was ineffective; CT suggested that there was a high uptake of multiple fluorodeoxyglucose (FDG) in many parts of the body; The lymph node biopsy was considered to be in accordance with the transparent vascular type of Castleman disease; Renal biopsy was used to return thrombotic microvascular disease with subacute renal tubulointerstitial nephropathy. In terms of treatment, the clinical condition of the patients was improved after methylprednisolone (60 mg, once a day), the temperature was normal, and the effusion in the serous cavity was better than before. The blood transfusion and platelet support therapy were intermittently given. Hemoglobin and platelets were increased in sex, and the urine volume increased to 1 000 mL/day. However, the platelet dropped at a later time, after 1 month of treatment with topizumab, the clinical condition of the patients was further improved. At present, the blood pigment and platelets returned to normal and had been separated from dialysis. TAFRO syndrome is a special subtype of idiopathic multicentric Castleman disease, and it is a group of systemic inflammatory diseases with its own characteristics. Its clinical manifestations and diagnosis and treatment are unique compared with other idiopathic multicentric Castleman diseases. For the enlargement of lymph nodes of unknown reasons, it is suggested to improve the lymph node biopsy actively. Renal insufficiency is an important part of TAFRO syndrome. Renal biopsy is of great significance to study the pathogenesis of TAFRO syndrome and to judge the prognosis of patients. The clinical diagnosis of the disease requires comprehensive clinical manifestations and the results of various examinations. Early diagnosis and early treatment of the disease can often achieve good clinical effect.

Key words: TAFRO syndrome, Castleman disease, Renal insufficiency, Lymph node biopsy, Renal biopsy

中图分类号: 

  • R692.5

图1

胸部CT可见双侧胸腔积液,心包少量积液"

图2

腹部CT可见腹水,腹腔多发渗出性改变(箭头示腹腔积液)"

图3

PET-CT示颈部多发FDG摄取增高淋巴结(箭头示FDG摄取增高淋巴结)"

图4

PET-CT可见肝脏增大,放射性分布基本均匀,脾脏增大,FDG摄取弥漫增高(左侧箭头示肝脏增大,右侧箭头示脾脏FDG摄取弥漫增高)"

图5

淋巴结活检可见正常淋巴滤泡结构,生发中心缩小,T区血管增生明显,淋巴窦扩张(HE ×100)"

图6

淋巴结HE染色高倍镜下可见组织细胞增生,小淋巴细胞淤滞(HE ×200)"

[1] Takai K, Nikkuni K, Momoi A, et al. Thrombocytopenia with reticulin fibrosis accompanied by fever, anasarca and hepatosplenomegaly: A clinical report of five cases [J]. J Clin Exp Hematop, 2013, 53(1):63-68.
doi: 10.3960/jslrt.53.63
[2] Castleman B, Towne VW. Case records of the Massachusetts General Hospital: Case No.40231 [J]. N Engl J Med, 1954, 250(23):1001-1005.
doi: 10.1056/NEJM195406102502308
[3] Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma [J]. Cancer, 1956, 9(4):822-830.
doi: 10.1002/(ISSN)1097-0142
[4] Kojima M, Nakamura S, Nishikawa M, et al. Idiopathic multicentric Castleman’s disease. A clinicopathologic and immunohistochemical study of five cases [J]. Pathol Res Pract, 2005, 201(4):325-332.
doi: 10.1016/j.prp.2005.01.006
[5] Kojima M, Nakamura N, Tsukamoto N, et al. Clinical implications of idiopathic multi centric castleman disease among Japanese: A report of 28 cases [J]. Int J Surg Pathol, 2008, 16(4):391-398.
doi: 10.1177/1066896908315812
[6] Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease [J]. Blood, 2017, 129(12):1646-1657.
doi: 10.1182/blood-2016-10-746933 pmid: 28087540
[7] Iwaki N, Fajgenbaum DC, Nabel CS, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease [J]. Am J Hematol, 2016, 91(2):220-226.
doi: 10.1002/ajh.24242
[8] Igawa T, Sato Y. TAFRO syndrome [J]. Hematol Oncol Clin North Am, 2018, 32(1):107-118.
doi: 10.1016/j.hoc.2017.09.009
[9] Masaki Y, Kawabata H, Takai K, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome [J]. Int J Hematol, 2016, 103(6):686-692.
doi: 10.1007/s12185-016-1979-1
[10] Kikuchi T, Shimizu T, Toyama T, et al. Successful treatment of TAFRO syndrome with tocilizumab, prednisone, and cyclophosphamide [J]. Intern Med, 2017, 56(16):2205-2211.
doi: 10.2169/internalmedicine.8522-16
[11] Yamaga Y, Tokuyama K, Kato T, et al. Successful treatment with cyclosporin A in tocilizumab-resistant TAFRO syndrome [J]. Intern Med, 2016, 55(2):185-190.
doi: 10.2169/internalmedicine.55.4710
[12] Shirai T, Onishi A, Waki D, et al. Successful treatment with tacrolimus in TAFRO syndrome [J]. Medicine, 2018, 97(23):e11045.
doi: 10.1097/MD.0000000000011045
[13] 王素霞, 邹古明, 章友康, 等. Castleman病肾损害的临床病理分析 [J]. 中华肾脏病杂志, 2009, 25(8):585-590.
[14] Kawashima M, Usui T, Okada H, et al. TAFRO syndrome: 2 cases and review of the literature [J]. Mod Rheumatol, 2017, 27(6):1093-1097.
doi: 10.3109/14397595.2015.1059982 pmid: 26052800
[1] 潘佳忻,朱赛楠,李双玲,王东信. 副肿瘤性天疱疮合并实体肿瘤的危重症患者术后远期结局的影响因素[J]. 北京大学学报(医学版), 2022, 54(5): 981-990.
[2] 周鑫,李文智. 肾细胞癌极致保肾时代的冷思考[J]. 北京大学学报(医学版), 2022, 54(4): 595-598.
[3] 安文成,闫慧娴,邓正照,陈芳,欧小虹,金红心,黄薇. 原发性醛固酮增多症肾上腺切除术后慢性肾功能不全1例[J]. 北京大学学报(医学版), 2021, 53(6): 1201-1204.
[4] 李西慧,肖锋,张思宇. 不停跳冠状动脉旁路移植术后急性肾损伤的影响因素探讨及3年随访结果[J]. 北京大学学报(医学版), 2017, 49(1): 131-136.
[5] 陈亮, 李建兴, 杨波, 胡卫国, 黄晓波, 王晓峰. 不同肾造瘘管及固定方式对肾结石合并肾功能不全患者术后并发症的影响[J]. 北京大学学报(医学版), 2011, 43(6): 878-881.
[6] 陈亮, 李建兴, 黄晓波, 杨波, 王佳, 王晓峰. 肾结石合并肾功能不全患者围手术期尿微量白蛋白与尿肌酐比值检测及意义[J]. 北京大学学报(医学版), 2011, 43(5): 757-760.
[7] ACS-PCI患者肾功能状态调查协作组, 霍勇, 何华. 急性冠状动脉综合征接受介入治疗患者肾功能状态多中心注册研究[J]. 北京大学学报(医学版), 2007, 39(6): 624-629.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!